Vanda Pharmaceuticals (VNDA) stock
VNDA's Quality Score rose 2 points on Fri, Nov 13, to -4. It closed near its high of the day (2 chart checks started).
Follow VNDA's trial news. Pro members can get an alert when Vanda Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on VNDA
| Since its Dec 2021 high | Down 78% |
| Latest filing | 10-Q, Oct 29 |
VNDA in the news
Big story
Vanda reports positive trial results for GLP-1 vomiting drug By Investing.com
VNDA closed +1.3% that day on 2.0x normal volume.
What's next
Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.
Expected to report Wed Feb 17, after the close
1 more date ahead: the conference, for Pro members.
VNDA catalysts
What's next for VNDA, and how long its cash lasts
Next step the company has named
Cash runway
About 4 quarters
Dilution on the horizon
- Shelf registration (S-3, filed Feb 12, 2026)
- At-the-market share sales program (S-3, filed Feb 12, 2026)
Insiders
Director Charles Cliff Duncan bought 10,000 shares on Nov 5. 6 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why VNDA scores -4
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
- +2Chart checks 2 of 14 firing right now, one point each
- −3Long-term trend below a falling 200-day average, down over one year, down over two years
- Size subtracts
- Profit subtracts
- Growth subtracts
- Volatility subtracts
- Cash flow subtracts
- Insider trades adds
How VNDA ranks in Biotech
VNDA is #188 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 188 |
Share count against a year before: VNDA +2.3%, MLYS +26%.
When does VNDA report earnings, and what happens after?
Expected to report Wed Feb 17, after the close (in 93 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What VNDA reported on Oct 28, 2026
The quarter
Sales of $69.8M, 24% more than a year ago; a loss of $0.37 a share, from $0.38.
“We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.”
Where the sales came from
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Fanapt | $38.8M | $36M | $31.2M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 29)
The outlook
| Measure | Figure |
|---|---|
| Total revenue | greater than $240 million |
In the company's words
“As certain of these activities began concluding in Q3 2026, operating expenses have decreased and Vanda expects operating expenses to decrease further in future quarters, as the remainder of these activities conclude.”
From its results filing (SEC filing · Oct 28)
The numbers
- $239M
- today
- $229M
- up 8.1% on the year
- -$140M
- last 12 months
Sales fell 2.7% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.3% a year over 5 years.
Close after the report, last 3
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | +11.4% | +1.3% | -3.0% |
| Aug 5, 2026 | -8.8% | +0.5% | +2.0% |
| May 6, 2026 | -5.7% | -14.1% | -13.6% |
VNDA sales and profit by year
Sales grew in five of the last seven years, to $216M in 2025. It made a profit in six of the eight years.
VNDA has 2 of 14 chart checks firing
VNDA RSI on Nov 13: 45.4, below its 50-day and 200-day averages
RSI 45.4, MACD above signal, below both averages. Not scored.
The deep dive on VNDA
- What it does and how it makes moneySEC filing · Feb 12, 2026SEC filing · Feb 12, 2026
- Where it stands
- What changed in its filingsSEC filing · Oct 29, 2026SEC filing · Feb 12, 2026, against the one of Feb 14, 2025SEC filing · Feb 12, 2026
- Who holds and trades it
- Against its closest peers
VNDA insider trades
One insider bought $38K across 3 filings in the last 6 months. No open-market sales on record. The newest:
VNDA's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold VNDA?
In ETFs: VNDA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
What Vanda Pharmaceuticals says it competes with
“The pharmaceutical industry, in particular, is highly competitive and includes a number of established large and mid-sized companies with greater financial, technical and personnel resources than we have and significantly greater commercial infrastructures than we have.”
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn VNDA's score around: 8 things
- 3 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does VNDA's Quality Score say?
VNDA scores -4 today, which Breakaway calls Poor. It is #188 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is VNDA's Quality Score?
VNDA scores -4 today, which Breakaway calls Poor (below zero). That is #188 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VNDA's -4.
Are insiders buying VNDA?
One insider bought $38K across 3 filings in the last 6 months. No open-market sales on record. The newest is Charles Cliff Duncan, Director, who bought $22K on Nov 5. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.